LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it has entered […]
Tag: Bard
BD Names John DeFord Chief Technology Officer
FRANKLIN LAKES, N.J., June 1, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today appointed John A. DeFord as executive vice president and chief technology officer. DeFord, 56, will report to Tom […]
IVC Filter Lawsuit News: C.R. Bard Ordered to Pay $3.6 Million at Conclusion of First Federal Bellwether Trial, Bernstein Liebhard LLP Reports
NEW YORK, April 2, 2018 /PRNewswire/ — C.R. Bard, Inc. has been ordered to pay $3.6 million to a Georgia woman who suffered serious complications after the company’s G2 inferior vena cava (IVC) filter fractured inside her body. The case was the first to go to trial […]
BD Statement On FTC Clearance Of Bard Acquisition
FRANKLIN LAKES, N.J., Dec. 22, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today’s clearance by the U.S. Federal Trade Commission (FTC) for BD to acquire C. R. Bard (NYSE: […]
Merit Medical Coughs Up $100M for Bard, BD’s Biopsy Assets
Shares of Merit Medical Systems have jumped more than 9 percent this morning after the company announced it plunked down $100 million for two product lines belonging to Becton, Dickinson and Company (BD). BD is selling the assets in connection with its acquisition of C.R. Bard Inc.(Bard). […]
BD Statement On European Commission Conditional Clearance Of Bard Acquisition
FRANKLIN LAKES, N.J., Oct. 18, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today’s clearance by the European Commission for BD to acquire C.R. Bard (NYSE: BCR), contingent on BD […]